Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery.

摘要: Pulmonary arterial hypertension (PAH) is a cardiopulmonary disorder characterized by increased blood pressure in the small arterioles supplying to lungs for oxygenation. Advances understanding of molecular and cellular biology techniques have led findings that PAH indeed cascade diseases exploiting multi-faceted complex pathophysiology, with proliferation vascular remodeling being key pathogenic events along several pathways involved. While current therapies do provide amelioration disease symptoms acute survival benefits, their full therapeutic potential hindered patient incompliance off-target side effects. To overcome issues related therapy devise more selective therapy, various novel are investigated treatment. In addition, inability deliver anti-PAH drugs site i.e., distal pulmonary has been one major challenges achieving improved outcomes efficacy. Several carriers explored increase selectivity currently approved act as suitable delivery investigational drugs. present review, we discussed pathways/targets including RhoA/Rho kinase, tyrosine endothelial progenitor cells, vasoactive intestinal peptide, miRNA therapeutics. We also site-specific drug therapeutics so improve efficacy This review will gainful insights into advances an emphasis on payload delivery.